[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632536":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":33,"locations":43,"responsibleParty":65,"collaborators":10,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":76,"maxAge":10,"enrollmentInfo":77,"targetDuration":10,"studyType":80,"phases":10,"briefSummary":81,"conditions":82,"keywords":86,"overallStatus":46,"whyStopped":10,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Cardiocentro Ticino","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Cangrelor MIDCAB Group (Prospective Cases)",null,"Patients prospectively enrolled to undergo MIDCAB surgery while receiving continuous cangrelor infusion at 0.75 μg\u002Fkg per minute. All prior oral antiplatelet therapy is discontinued, and platelet function is monitored daily with Multiplate® testing. Data collected include perioperative safety, bleeding outcomes, laboratory values, and clinical events.",[13],"Procedure: Cangrelor-guided MIDCAB surgery (for the prospective cases)",{"label":15,"type":10,"description":16,"interventionNames":17},"Aspirin MIDCAB Group (Historical Controls)","Retrospective patients who previously underwent MIDCAB surgery under aspirin therapy, with or without prior bridging with cangrelor. Relevant perioperative and clinical data are extracted from the institutional database for comparison with the prospective cases.",[18],"Procedure: Aspirin MIDCAB surgery (for the historical controls)",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"PROCEDURE","Cangrelor-guided MIDCAB surgery (for the prospective cases)","Cangrelor-guided MIDCAB surgery: Patients undergo minimally invasive direct coronary artery bypass (MIDCAB) with continuous intravenous cangrelor infusion at 0.75 μg\u002Fkg per minute. Prior oral antiplatelet therapy is discontinued, and platelet function is monitored daily using Multiplate® testing. Cangrelor infusion is started when platelet aggregation reaches predefined thresholds and continued throughout surgery until it is safe to restart oral antiplatelet therapy.",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"Aspirin MIDCAB surgery (for the historical controls)","Aspirin MIDCAB surgery: Historical control patients underwent MIDCAB under aspirin therapy, with or without prior bridging with cangrelor. Perioperative management follows standard care, including anticoagulation with unfractionated heparin during surgery and routine monitoring of laboratory and clinical outcomes.",[15],[30],{"name":31,"affiliation":5,"role":32},"Marco Valgimigli, Prof. Dr. Med.","PRINCIPAL_INVESTIGATOR",[34,39],{"name":35,"role":36,"phone":37,"phoneExt":10,"email":38},"Marco Valgimigli, Prof Dr Med","CONTACT","+41 91 811 51 11","marco.valgimigli@eoc.ch",{"name":40,"role":36,"phone":41,"phoneExt":10,"email":42},"Servizio di Ricerca Cardiovascolare Cardiocentro","+41 (0)91 811 53 04","enrico.frigoli@eoc.ch",[44],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Istituto Cardiocentro Ticino","RECRUITING","Lugano","Ch\u002Fti","6900","Switzerland","CH",{"type":53,"coordinates":54},"Point",[55,56],8.96004,46.01008,{"lat":56,"lon":55},[59,63,64],{"name":60,"role":36,"phone":61,"phoneExt":10,"email":62},"Servizio di Ricerca Cardiovascolare","+41 (0) 91 811 5055","src.ICCT@eoc.ch",{"name":45,"role":36,"phone":61,"phoneExt":10,"email":10},{"name":31,"role":32,"phone":10,"phoneExt":10,"email":10},{"type":32,"investigatorFullName":66,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Marco Valgimigli","Cardiology Chief Prof. Dr. Med","100632536","minimally-invasive-coronary-artery-bypass-supported-by-cangrelor-100632536",false,"NCT07514962","Minimally Invasive Coronary Artery Bypass Supported by Cangrelor","MINOTAUR","Inclusion Criteria for the historical control arm:\n\n* Age ≥18 years old\n* CABG with IMA-LAD graft in MIDCAB technique\n\nInclusion criteria for the prospective arm:\n\n* Age ≥18 years old\n* CABG with IMA-LAD graft in MIDCAB technique\n* Signed informed consent\n\nExclusion criteria for the historical control arm\n\n* Administration of fibrinolytics or GP IIb\u002FIIIa inhibitors\n* Previous intracranial hemorrhage\n* Known bleeding diathesis\n* Patients undergoing concomitant PCI and MIDCAB\n* Severe renal or liver disease\n* Pregnancy or breast feeding\n\nExclusion criteria for the prospective arm\n\n* Unconsciousness\n* Known hypersensitivity to study drug (cangrelor)\n* Recent administration of fibrinolytics or GP IIb\u002FIIIa inhibitors\n* Previous intracranial hemorrhage\n* Known bleeding diathesis\n* Patients undergoing concomitant PCI and MIDCAB\n* Severe renal or liver disease\n* Pregnancy or breast feeding","ALL","18 Years",{"count":78,"type":79},30,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to find out whether it is safe and practical to perform MIDCAB surgery (a minimally invasive heart bypass procedure) while patients receive a continuous cangrelor infusion during the operation. Cangrelor is a medicine that helps prevent blood clots and works quickly through a vein drip.\n\nThe study compares patients receiving cangrelor during surgery to patients who had the same surgery in the past while on aspirin, with or without cangrelor given beforehand.\n\nStudy Question: Can MIDCAB surgery be safely performed under cangrelor infusion, without increasing the risk of bleeding or other complications?\n\nHypothesis: Using cangrelor during MIDCAB surgery is safe and feasible, and it provides effective protection against blood clots during the procedure.\n\nThis study will help doctors understand whether intraoperative cangrelor can improve patient safety and outcomes in minimally invasive heart surgery.",[83,84,85],"Coronary Artery Disease","Antiplatelet Therapy","Minimally Invasive Coronary Revascularization Surgery",[87,88,83,89,90,91,92,93,94,95],"Minimally Invasive Direct Coronary Artery Bypass","MIDCAB Surgery","Cangrelor","Perioperative Antiplatelet Therapy","Platelet Function Monitoring","Bridging Therapy","Cardiac Surgery","Intraoperative Antiplatelet Management","Bleeding Risk","2026-04-13",{"date":98,"type":99},"2026-04-14","ACTUAL",{"date":101,"type":99},"2024-05-12",{"date":103,"type":79},"2028-01-01",{"name":5,"class":6},1]